about
Human recombinant activated protein C for severe sepsisRecombinant human activated protein C resets thrombin generation in patients with severe sepsis - a case control study.Inhibition of lipopolysaccharide-induced interferon regulatory factor 3 activation and protection from septic shock by hydroxystilbenes.Recombinant human activated protein C, drotrecogin alfa (activated): a novel therapy for severe sepsis.Coagulation inhibitors in the treatment of sepsis.The anti-inflammatory actions of antithrombin--a review.Bench-to-bedside review: the role of activated protein C in maintaining endothelial tight junction function and its relationship to organ injury.An evaluation of the cost effectiveness of drotrecogin alfa (activated) relative to the number of organ system failures.Drotrecogin alfa: a role in emergency department treatment of severe sepsis?Sepsis strategies: an ICU package?Thromboelastography as a better indicator of hypercoagulable state after injury than prothrombin time or activated partial thromboplastin timeThe anticoagulant protein C pathway.Inflammation-induced microvascular dysfunction in obesity - A translational approach.Loss of endothelial protein C receptors links coagulation and inflammation to parasite sequestration in cerebral malaria in African childrenInnate recognition of bacteria: potential therapeutic targets for bacterial sepsis.Statins in sepsis.Gene expression profiling of the early pulmonary response to hyperoxia in mice.Modulation of thrombomodulin-dependent activation of human protein C through differential expression of endothelial Smads.Decreased Activity of the Protein C Anticoagulant Pathway in the Early Hours of Paroxysmal Atrial Fibrillation.Impact of chemotherapy on thrombin generation and on the protein C pathway in breast cancer patients.A definite role for treatment with activated protein C in sepsis? Yes.Mutations in the thrombomodulin gene are rare in patients with severe thrombophilia.Antithrombin and protein C in systemic inflammatory response syndrome.Identification of Genetic Aberrations in Thrombomodulin Gene in Patients With Recurrent Venous Thromboembolism.A novel frameshift mutation Gly239Serfs*8 in the PROC gene results in protein C deficiency in a Korean patient.
P2860
Q24242859-FAB8574B-5193-4662-BBF9-95555E704AA2Q24813299-E9CC109E-54AB-4620-B292-1BFB8C00535DQ34130251-A90F7B11-4163-4341-87EE-372F5CBDD60EQ34443368-E325EFB0-6DD9-4F02-87D9-CB1777724EF4Q34481969-9F936EA3-8036-4C1B-A9DF-5E12222A6B62Q34777707-0D4F3921-1F70-41D5-92E3-B0C14831BB45Q35629866-141DF36A-856D-4D4F-B72D-A88E4513657DQ35642546-60AA0715-4722-4BED-804E-72D2DAE31E19Q35850483-777A2138-3CD8-494A-9078-8C0368C2A2CDQ35969932-210E3889-ABBB-45C5-B7F4-F5C5EB00864DQ36152281-2781AD42-D2A8-4275-96D2-FECAA62AC68DQ36156027-9D54243C-42EE-49C0-817E-C7AB49EAE76BQ36170508-10A474BE-E871-4030-BFC8-E865EA35D032Q37065724-B8DC1375-2D90-4F91-A7C6-FB9980B07F4CQ37755268-38D89CE9-2C53-4E95-9763-EAA202079186Q37867264-EEAE4E5D-BD2F-41F8-8A50-1D7878D97F91Q38354410-FC0588BB-9CB4-4373-A56D-8D504EC2A96CQ38361465-5C0C7700-FE8A-4D3A-8DE2-EA3C9F5ECEC9Q39676339-982D3770-457B-49C7-AC81-3740A759B95DQ42745163-E1593FAA-67B1-473D-B476-661245DAA2FDQ43438582-B333E703-14CA-4CCA-95FE-41155C5CCEF6Q45888062-39367C41-B36B-472D-9A16-3BD59767E400Q48627214-B0F3CDC0-4A25-4FF2-B4D1-4BC171F5DC39Q51220285-B4386EFD-4D90-42B0-AAB3-08E3220FA206Q53376265-02FFB9F0-B0DC-46F9-9943-2245ECCF2CA5
P2860
description
2000 nî lūn-bûn
@nan
2000 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
The protein C pathway.
@ast
The protein C pathway.
@en
The protein C pathway.
@nl
type
label
The protein C pathway.
@ast
The protein C pathway.
@en
The protein C pathway.
@nl
prefLabel
The protein C pathway.
@ast
The protein C pathway.
@en
The protein C pathway.
@nl
P1476
The protein C pathway.
@en
P2093
P356
10.1097/00003246-200009001-00010
P407
P433
P577
2000-09-01T00:00:00Z